Investigating how iron metabolism affects treatment resistance in pancreatic cancer
Targeting iron metabolism in pancreatic adenocarcinoma to overcome KRAS inhibitor therapeutic resistance
['FUNDING_R01'] · DANA-FARBER CANCER INST · NIH-11162898
This study is looking at how some pancreatic cancer patients become resistant to new treatments and aims to find better ways to help them by understanding how iron in the body affects cancer cells, which could lead to more effective therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11162898 on ClinicalTrials.gov |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer with low survival rates. It aims to understand how resistance to KRAS inhibitors, a new type of cancer treatment, develops in patients. By exploring the relationship between iron metabolism and cancer cell survival, the study seeks to identify new combination therapies that could enhance the effectiveness of existing treatments. Patients may benefit from insights that could lead to improved therapeutic strategies against this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are experiencing resistance to KRAS inhibitor therapies.
Not a fit: Patients with other types of cancer or those not undergoing KRAS inhibitor treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways to overcome treatment resistance in various cancers, suggesting this approach may be viable.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MANCIAS, JOSEPH D — DANA-FARBER CANCER INST
- Study coordinator: MANCIAS, JOSEPH D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: addictive disorder, anti-cancer